KRAS and neoplasm: Idylla ctKRAS and OncoBEAM plasma testing results were compared with KRAS mutation results obtained by SOC FFPE tumor tissue testing in 43 mCRC patients that were OncoBEAM KRAS-MUT+ with MAF values <1%.